News
Latest News
Hypha are excited to announce they have relocated from Slough to Milton Park in Oxfordshire, one of the largest science clusters in the UK.
Metabolites derived from any human flavin-containing monooxygenase (FMO) subtype can now be produced as a service offering at Hypha. Recombinant enzymes of all five forms of human FMOs have been cloned into E.coli to provide a mechanism to access scalable quantities of FMO derived metabolites.
Great to see Hypha recognised for producing a glucuronide metabolite of praliciguat (M3) in the paper just out in the journal Pharmacology Research & Perspectives.
Hypha remain fully operational and are monitoring the COVID-19 situation closely. We have implemented a number of measures in response to the guidelines issued by the UK Government to ensure that our clients’ projects proceed as planned, while preserving the health and safety of our staff and the wider community.
As a leading specialist CRO for drug metabolite provision, Hypha has formed a partnership with Cypex Limited, experts in the provision of a variety of recombinant xenobiotic metabolising enzymes, wherein Hypha will scale-up and purify metabolites made by Cypex enzymes.
We are excited to announce the official launch of our One-Stop Metabolite Shop, which offers a complete solution for pharma and agrochemical companies to access small molecule metabolites.
Hypha is able to offer clients a combination of a number of biological and chemical techniques, meaning that clients can quickly establish a method to identify and scale up any type of metabolite.
Hypha are looking forward to presenting two posters at the ISSX meeting held in Portland US from 28th to 31st July 2019.
One is a joint poster with Cyclerion Therapeutics on “Use of Microbial Biotransformation to Produce Scalable Quantities of a Glucuronidated Metabolite of the Clinical Stage Soluble Guanylate Cyclase Stimulator Praliciguat” (P10).
Our newsletter this quarter looks at the use of microbial biotransformation to synthesize glucuronide metabolites, with a particular emphasis on the production of acyl glucuronides, arising from the metabolism of carboxylic acid-containing drugs.
Hypha are excited to present a poster describing the application of PolyCYPs enzyme kits to create oxidised derivatives of drug candidates. In this project conducted joint with AstraZeneca, we show that PolyCYPs enzymes were able to synthesize all monohydroxylated derivatives of a drug lead candidate.
We have just published an article on “Accessing Difficult-to-Synthesise Metabolites in Drug Development Programmes” in the April 2019 edition of European Biopharmaceutical Review. Access to major and/or disproportionate metabolites is important to ensure adherence to regulatory guidelines issued by the FDA and EMA, as well as to comply with internal safety standards set by pharmaceutical companies themselves.
Hypha are pleased to announce the official launch of their PolyCYPs® kit, which provide a fast and easy way to access CYP-derived metabolites and oxidised derivatives of drugs.
Enzymes in the kit have been mined from some of Hypha’s most talented actinomycete bacteria, providing a wide variety of CYPs proven to have a high success rate of producing human metabolites and other hydroxylated derivatives.
Lisbet has >20 years’ experience in challenging organic synthesis, process chemistry, CMC development and project management within the pharmaceutical industry (H. Lundbeck A/S, Novo Nordisk Pharmatech A/S), biotech start-ups (Lipideon A/G) and multiple academic institutions (Max Planck Institute of Coal Research Germany, ETH Zurich Switzerland, Harvard University USA, Technical University of Denmark).
Stay up to date with the latest news from Hypha Discovery
Sign up for our quarterly newsletters and monthly "Metabolite Tales" blog
Ready to begin? Our scientists are available to talk through your requirements
Hypha Discovery is a UK-based CRO supporting pharmaceutical and agrochemical companies worldwide through the production of metabolites and new derivatives of drugs and agrochemicals in discovery and development.
Resources
Cookie Policy | Privacy Policy | Website Terms and Conditions
© Hypha Discovery 2021. All Rights Reserved. Website by Fifteen.co.uk